The sotrovimab therapeutic is active against Omicron, but is still very limited in supply. We are not currently accepting orders from network providers for treatment. The following therapeutics are less effective against the Omicron variant:įor this reason, effective December 30, 2021, we have paused the Blue Cross ® Blue Shield ® of Arizona (BCBSAZ) monoclonal antibody (mAb) treatment program. Department of Health and Human Services have paused the distribution of the monoclonal antibody drugs that have been effectively used against earlier strains of the virus. With the rise of COVID-19 infections from the Omicron variant, the FDA and U.S. BCBSAZ has temporarily paused the monoclonal antibody treatment program in accordance with federal guidance
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |